卡维地洛与美托洛尔治疗轻中度高血压病的疗效比较

Comparison of efficacy with carvedilol and metoprolol in treating mild to moderate essential hypertension

目的观察卡维地洛治疗轻、中度高血压病的临床疗效和安全性。方法140例轻、中度高血压病人随机分为卡维地洛组与美托洛尔组各70例，分别用卡维地洛10～20mg，口服，2次／d与美托洛尔25—50mg，口服，2次／d，共6周。结果卡维地洛组总有效率为85．7％，显效率为58．6％；美托洛尔组总有效率为78．6％，显效率为48．6％；两组疗效比较差异无统计学意义（P〉0．05）。两组第6周末心率与治疗前相比差异均有统计学意义（P〈0．05）。卡维地洛组第6周末动态血压监测的收缩压（SBP）和舒张压（DBP）的T／P值分别为61．2％和50．3％。两组不良反应的发生率分别为21．4％及20．0％，均较轻微。结论国产卡维地洛治疗轻、中度高血压病有效、安全。

Objective To observe the clinical efficacy and safety of carvedilol in treating essential hypertension and compare with metoprolol. Methods One hundred and forty patients with mild tomoderate essential hypertension were divided into two groups： carvedilol group received carvedilol 10 -20 mg, took orally,2 times/d and metoprolol group received metoprolol 25 -50 mg, took orally,2 times/d, for six weeks. Results The total effective rates were 85.7% for carvedilol group, and 78.6% for metoprolol group, respectively. The obvious effctive rates were 58.6% for carvedilol group, and 48.6% for metoprolol group, respectively. There was no significant difference between the two groups（ P 〉 0.05 ）. After six weeks treatment,the heart rates of all patients were significantly decreased. At the end of six weeks, the T/P of SBP and DBP of ambulatory blood pressure monitoring were 61.2%, and 50. 3% in carvedilol group. The most adverse reactions were 21.4% , 20. 0%, respectively, but mild and tolerable. Conclusion Carvedilol is effective, safe in treating mild to rood-crate essential hypertension.